Bleb needling with subconjunctival injection of sodium hyaluronate 1.4%: 1-year outcomes.

Research output: Contribution to journalArticle

Standard

Bleb needling with subconjunctival injection of sodium hyaluronate 1.4%: 1-year outcomes. / Shafi, F; Agrawal, P; Holder, Roger; Sung, V.

In: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, Vol. 46, No. 6, 01.12.2011, p. 537-42.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{f1e6590349b64fcbb439bce6ac312a14,
title = "Bleb needling with subconjunctival injection of sodium hyaluronate 1.4%: 1-year outcomes.",
abstract = "OBJECTIVES To assess the safety and efficacy of 5-fluorouracil (5-FU)-augmented bleb needling revision (BNR) with subconjunctival Healon GV (sodium hyaluronate 1.4%) over a 12-month follow-up. DESIGN Retrospective consecutive case series. PARTICIPANTS We studied 54 patients who had undergone primary BNR with adjunctive 5-FU and routine subconjunctival Healon GV between 2004 and 2007. METHODS BNR was performed using multiple puncturing motions through the bleb: a 0.4 mL Healon GV injection between the bleb and conjunctiva; and a 5-FU (10 mg in 0.4 mL) injection into the substance of Healon GV. Success was defined as follows: (1) complete success, indicating intraocular pressure (IOP) reduction ≥ 20% and to ≤ 21 mm Hg but > 5 mm Hg without antiglaucoma medication; or (2) qualified success, indicating IOP reduction ≥ 20% and to ≤ 21 mm Hg but > 5 mm Hg with or without antiglaucoma medication. Patients requiring additional filtration surgery during the 12-month follow-up period were considered failures. RESULTS Data collection was completed for 53 eyes of 46 patients. The IOP fell from a preoperative mean of 22.7 ± 7.95 mm Hg to 16.3 ± 4.34 mm Hg at 12 months (p <0.001). The complete success rate was 26.4%; the qualified success rate was 43.4%. Of the eyes studied, 28 (52.8%) achieved IOPs of ≤ 16 mm Hg at 12 months. Complications occurred in 16 eyes (30%), and 3 required surgical intervention. CONCLUSIONS Subconjunctival Healon GV in 5-FU-augmented bleb needling revision is a relatively safe and effective technique for reducing IOP in the short to medium term, and it involves few significant complications.",
author = "F Shafi and P Agrawal and Roger Holder and V Sung",
year = "2011",
month = dec,
day = "1",
doi = "10.1016/j.jcjo.2011.09.005",
language = "English",
volume = "46",
pages = "537--42",
journal = "Canadian journal of ophthalmology. Journal canadien d'ophtalmologie",
issn = "0008-4182",
publisher = "Canadian Ophthalmological Society",
number = "6",

}

RIS

TY - JOUR

T1 - Bleb needling with subconjunctival injection of sodium hyaluronate 1.4%: 1-year outcomes.

AU - Shafi, F

AU - Agrawal, P

AU - Holder, Roger

AU - Sung, V

PY - 2011/12/1

Y1 - 2011/12/1

N2 - OBJECTIVES To assess the safety and efficacy of 5-fluorouracil (5-FU)-augmented bleb needling revision (BNR) with subconjunctival Healon GV (sodium hyaluronate 1.4%) over a 12-month follow-up. DESIGN Retrospective consecutive case series. PARTICIPANTS We studied 54 patients who had undergone primary BNR with adjunctive 5-FU and routine subconjunctival Healon GV between 2004 and 2007. METHODS BNR was performed using multiple puncturing motions through the bleb: a 0.4 mL Healon GV injection between the bleb and conjunctiva; and a 5-FU (10 mg in 0.4 mL) injection into the substance of Healon GV. Success was defined as follows: (1) complete success, indicating intraocular pressure (IOP) reduction ≥ 20% and to ≤ 21 mm Hg but > 5 mm Hg without antiglaucoma medication; or (2) qualified success, indicating IOP reduction ≥ 20% and to ≤ 21 mm Hg but > 5 mm Hg with or without antiglaucoma medication. Patients requiring additional filtration surgery during the 12-month follow-up period were considered failures. RESULTS Data collection was completed for 53 eyes of 46 patients. The IOP fell from a preoperative mean of 22.7 ± 7.95 mm Hg to 16.3 ± 4.34 mm Hg at 12 months (p <0.001). The complete success rate was 26.4%; the qualified success rate was 43.4%. Of the eyes studied, 28 (52.8%) achieved IOPs of ≤ 16 mm Hg at 12 months. Complications occurred in 16 eyes (30%), and 3 required surgical intervention. CONCLUSIONS Subconjunctival Healon GV in 5-FU-augmented bleb needling revision is a relatively safe and effective technique for reducing IOP in the short to medium term, and it involves few significant complications.

AB - OBJECTIVES To assess the safety and efficacy of 5-fluorouracil (5-FU)-augmented bleb needling revision (BNR) with subconjunctival Healon GV (sodium hyaluronate 1.4%) over a 12-month follow-up. DESIGN Retrospective consecutive case series. PARTICIPANTS We studied 54 patients who had undergone primary BNR with adjunctive 5-FU and routine subconjunctival Healon GV between 2004 and 2007. METHODS BNR was performed using multiple puncturing motions through the bleb: a 0.4 mL Healon GV injection between the bleb and conjunctiva; and a 5-FU (10 mg in 0.4 mL) injection into the substance of Healon GV. Success was defined as follows: (1) complete success, indicating intraocular pressure (IOP) reduction ≥ 20% and to ≤ 21 mm Hg but > 5 mm Hg without antiglaucoma medication; or (2) qualified success, indicating IOP reduction ≥ 20% and to ≤ 21 mm Hg but > 5 mm Hg with or without antiglaucoma medication. Patients requiring additional filtration surgery during the 12-month follow-up period were considered failures. RESULTS Data collection was completed for 53 eyes of 46 patients. The IOP fell from a preoperative mean of 22.7 ± 7.95 mm Hg to 16.3 ± 4.34 mm Hg at 12 months (p <0.001). The complete success rate was 26.4%; the qualified success rate was 43.4%. Of the eyes studied, 28 (52.8%) achieved IOPs of ≤ 16 mm Hg at 12 months. Complications occurred in 16 eyes (30%), and 3 required surgical intervention. CONCLUSIONS Subconjunctival Healon GV in 5-FU-augmented bleb needling revision is a relatively safe and effective technique for reducing IOP in the short to medium term, and it involves few significant complications.

U2 - 10.1016/j.jcjo.2011.09.005

DO - 10.1016/j.jcjo.2011.09.005

M3 - Article

C2 - 22153643

VL - 46

SP - 537

EP - 542

JO - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

JF - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

SN - 0008-4182

IS - 6

ER -